Bubs Australia rises as co starts infant formula clinical trial in US

Bubs Australia

07/09/2023 01:44

** Shares of dairy firm Bubs Australia Ltd  BUB.AX  rise as
much as 3% to A$0.170 
    ** Bubs stock on track to snap a three-day losing streak;
shares traded flat in last two sessions 
    ** Co announces U.S.-based infant formula clinical trial
    ** Co starts nationwide enrolment for its growth monitoring
study (GMS) clinical trial  
    ** Says study is designed to evaluate growth, tolerance, and
safety of new infant formulas 
    ** Co plans to submit results from GMS to U.S. Food and Drug
Administration (FDA) by Sept 2024 with full infant formula
submission by Oct 2024 
    ** Bubs stock down 45% YTD, as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))